What is the main difference between Epithalon and Sigumir?

Epithalon is a Longevity peptide while Sigumir is a Repair & Recovery peptide. Epithalon has Low evidence (28 sources) and Sigumir has Low evidence (7 sources).

Which has more clinical evidence, Epithalon or Sigumir?

Epithalon has more clinical evidence with 5 human studies compared to 1 for Sigumir. Overall, Epithalon has Low evidence strength while Sigumir has Low.

Are Epithalon and Sigumir FDA approved?

Epithalon has Low clinical evidence and is not FDA-approved for general use. Sigumir has Low clinical evidence and is not FDA-approved for general use. Always verify current regulatory status with official sources.

Can Epithalon and Sigumir be combined?

There is no published research on combining Epithalon and Sigumir. The safety and efficacy of any combination is unknown without clinical data.

Longevity Comparison

Epithalon vs Sigumir

Comparison of Epithalon (Low evidence) and Sigumir (Low evidence).

Last updated: February 12, 2026

Epithalon

Low Evidence

View full dossier

Sigumir

Low Evidence

View full dossier

Overview

Epithalon and Sigumir are both studied in the peptide research space.

Epithalon: A synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to activate telomerase and extend lifespan.

Sigumir: A cytamin-class peptide supplement derived from cartilage tissue, part of the Russian bioregulator framework.

Evidence Comparison

Aspect	Epithalon	Sigumir
Evidence Level	Low	Low
Human Studies	5	1
Preclinical Studies	15	5
Total Sources	28	7

Key Differences

Aspect	Epithalon	Sigumir
Category	Longevity	Repair & Recovery
Evidence Strength	Low	Low
Total Sources	28	7
Human Studies	5	1

Summary

Epithalon: Low evidence with 28 total sources (5 human)
Sigumir: Low evidence with 7 total sources (1 human)

This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.

View Full Dossiers

Epithalon Evidence Dossier Sigumir Evidence Dossier

Stay Updated on Peptide Comparisons

Get notified when we publish new comparison dossiers and evidence reviews.

No spam. Unsubscribe anytime.

Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.